MarginsXMarginsX
Home › Markets › Health Care › LSTA

Lisata Therapeutics Inc. (LSTA)

LSTA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.09
-9.92% on the day
Market cap
$11.8M
Nano cap
Revenue · 2025
$170K
-83.0% on 2024
Net income · 2025
-$16.6M
-9756.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/320017/000032001726000023/0000320017-26-000023-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerLSTA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000320017
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$170K
Net income-$16.6M
Operating income-$18.2M
Net margin-9756.5%
Operating margin-10711.2%
Revenue growth-83.0%
Cash$16.0M
Total assets$17.7M
P/E (computed)Net income was not positive
P/S (computed)69.3×

Warning signs

Cash runway
10.2 months
$10.4M cash at June 30, 2026
Share count, 1 year
+22.5%
2025-11-06 to 2026-11-13 · +32.7% over 3 years
Going-concern doubt
Yes
10-Q filed November 13, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"After evaluating the conditions described above in the aggregate, the Company has concluded that there is substantial doubt about its ability to continue as a going concern."
10-Q 2026-11-13
Cash and burn$10.4M cash; operating cash flow -$3.1M a quarter.Report 2026-06-30
Shares outstanding10,804,066 (2026-11-13); 8,820,733 a year earlier; 8,139,449 three years earlier.Cover page 2026-11-13
Reverse splits, 3 years1; latest on 2026-09-17Source 2026-09-17
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-11-12
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorGrant Thornton LLP, New York, New York, United StatesPCAOB Form AP 2026-03-16
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$0-$2.9M-$2.6M$10.4MNo debt tags$100K10-Q 2026-08-06
Q1 2026
2026-03-31
$0-$4.5M-$3.1M$13.1MNo debt tags$170K10-Q 2026-05-11
Q4 2025
2025-12-31
$100K-$3.0M-$3.2M$16.0MNo debt tags$170K10-K 2026-03-12
Q3 2025
2025-09-30
$0-$4.2M-$3.3M$19.0MNo debt tags$1.1M10-Q 2025-11-06
Q2 2025
2025-06-30
$70K-$4.7M-$4.0M$16.8MNo debt tags$1.1M10-Q 2026-08-06
Q1 2025
2025-03-31
$0-$4.7M-$5.4M$20.2MNo debt tags$1.0M10-Q 2026-05-11
Q4 2024
2024-12-31
$1.0M-$4.6M-$4.5M$16.2MNo debt tags$1.0M10-K 2026-03-12
Q3 2024
2024-09-30
$0-$4.9M-$2.5M$19.5MNo debt tags$010-Q 2025-11-06

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-11-12
Latest annual report10-K/A2026-04-28
Latest quarterly / interim10-Q2026-11-13
Latest current report8-K/A2026-11-12
Latest proxyDEFA14A2026-11-09

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+17.5%
1 month+12.0%
3 months+7.1%
Year to date-34.9%
1 year-41.5%
From 52-week high-76.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
BIVIBioVie Inc.$1.08-4.42%$11.6M
DAREDare Bioscience Inc.$0.5842-11.13%$11.5M
QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares$1.44-10.56%$12.2M
ASBPAspire-Lakewood Holdings Inc.$8.06-5.29%$11.3M
OPTHOptimi Health Corp. Common Shares$2.15-4.44%$12.3M
RADXRadiopharm Theranostics Limited$0.7676+1.00%$11.1M
PTNPalatin Technologies Inc.$6.13-1.69%$10.9M
HINDVyome Holdings Inc.$1.53-3.16%$10.7M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier